Last reviewed · How we verify
Intravenous rhPro-UK
Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots.
Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots. Used for Acute ischemic stroke, Acute myocardial infarction, Pulmonary embolism.
At a glance
| Generic name | Intravenous rhPro-UK |
|---|---|
| Also known as | Intravenous PUK, Intravenous recombinant human prourokinase |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Drug class | Thrombolytic agent |
| Target | Plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
rhPro-UK is a serine protease that activates the fibrinolytic cascade by converting inactive plasminogen into active plasmin, which degrades fibrin in thrombi. This mechanism enables clot dissolution in acute thrombotic conditions. The drug is administered intravenously to achieve systemic thrombolysis.
Approved indications
- Acute ischemic stroke
- Acute myocardial infarction
- Pulmonary embolism
Common side effects
- Bleeding/hemorrhage
- Intracranial hemorrhage
- Allergic reaction
- Hypotension
Key clinical trials
- Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) (PHASE3)
- Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits (PHASE4)
- Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer (PHASE3)
- Intravenous Thrombolysis and NOAC (PHASE3)
- Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months (PHASE3)
- ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE) (PHASE3)
- A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous rhPro-UK CI brief — competitive landscape report
- Intravenous rhPro-UK updates RSS · CI watch RSS
- First Affiliated Hospital Xi'an Jiaotong University portfolio CI